Precision medicine is transforming how therapies are developed and delivered. However, turning scientific discoveries into patient impact requires more than innovation alone - it demands the right combination of genomic expertise, regulatory knowledge and clinical execution.

That's why ARC Regulatory is working alongside SOPHiA GENETICS, a global leader in AI-powered genomic analytics, to support the development of biomarker-driven therapies and personalised healthcare.

Supporting Precision Medicine at Every Stage

As targeted therapies become increasingly important, sponsors need trusted partners who can help navigate the complexities of biomarker identification, genomic testing, and regulatory compliance.

By combining SOPHiA GENETICS' advanced analytics platform with ARC's expertise in regulatory strategy, clinical trial assay development, and clinical research services, we can provide a more integrated approach to precision medicine studies.

Strengthening Europe's Precision Medicine Infrastructure

A key part of this collaboration is ARC Laboratory in Belfast. Our CAP-accredited and ISO15189-certified laboratory is designed to support advanced genomic testing while maintaining the highest standards of quality and compliance.

Together, ARC and SOPHiA GENETICS are helping sponsors access the tools and expertise needed to advance innovative therapies from development through to clinical application.

Why Partnerships Matter

The future of precision medicine will be built through collaboration. By bringing together complementary expertise, organisations can accelerate innovation, reduce complexity, and create more efficient pathways for drug development. This partnership reflects ARC's commitment to supporting pharmaceutical and biotechnology companies as they navigate an increasingly complex clinical and regulatory landscape.

Looking Ahead

As precision medicine continues to evolve, strategic partnerships will play a vital role in connecting scientific discovery with patient outcomes.

Seamus Kearney, CEO of ARC Regulatory, says: "Precision medicine relies on bringing together the right expertise at the right time. Our partnership with SOPHiA GENETICS combines advanced genomic technologies with ARC's regulatory and clinical development capabilities, helping sponsors accelerate innovation and ultimately improve outcomes for patients."

We look forward to working alongside SOPHiA GENETICS and our other industry partners to help shape the future of personalised medicine.